These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 24821916)

  • 1. Who will develop new antibacterial agents?
    Cole ST
    Philos Trans R Soc Lond B Biol Sci; 2014; 369(1645):20130430. PubMed ID: 24821916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sources of innovation: an assessment of intellectual property.
    Kinch MS; Raffo J
    Drug Discov Today; 2015 May; 20(5):500-4. PubMed ID: 25499663
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug development: Time for teamwork.
    May M
    Nature; 2014 May; 509(7498):S4-5. PubMed ID: 24784427
    [No Abstract]   [Full Text] [Related]  

  • 4. Antibiotic research and development: business as usual?
    Harbarth S; Theuretzbacher U; Hackett J;
    J Antimicrob Chemother; 2015; 70(6):1604-7. PubMed ID: 25673635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time for a change: addressing R&D and commercialization challenges for antibacterials.
    Payne DJ; Miller LF; Findlay D; Anderson J; Marks L
    Philos Trans R Soc Lond B Biol Sci; 2015 Jun; 370(1670):20140086. PubMed ID: 25918443
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibiotics: the changing regulatory and pharmaceutical industry paradigm.
    Bax R; Green S
    J Antimicrob Chemother; 2015 May; 70(5):1281-4. PubMed ID: 25634991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fix the antibiotics pipeline.
    Cooper MA; Shlaes D
    Nature; 2011 Apr; 472(7341):32. PubMed ID: 21475175
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibacterial R&D incentives.
    Laxminarayan R; Powers JH
    Nat Rev Drug Discov; 2011 Sep; 10(10):727-8. PubMed ID: 21959280
    [No Abstract]   [Full Text] [Related]  

  • 9. What are the economic barriers of antibiotic R&D and how can we overcome them?
    Renwick M; Mossialos E
    Expert Opin Drug Discov; 2018 Oct; 13(10):889-892. PubMed ID: 30175625
    [No Abstract]   [Full Text] [Related]  

  • 10. Reinventing the antimicrobial pipeline in response to the global crisis of antimicrobial-resistant infections.
    Singer AC; Kirchhelle C; Roberts AP
    F1000Res; 2019; 8():238. PubMed ID: 30906539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. China spurs pharma innovation.
    Hughes B
    Nat Rev Drug Discov; 2010 Aug; 9(8):581-2. PubMed ID: 20671751
    [No Abstract]   [Full Text] [Related]  

  • 12. 2011 in reflection.
    Mullard A
    Nat Rev Drug Discov; 2012 Jan; 11(1):6-8. PubMed ID: 22212664
    [No Abstract]   [Full Text] [Related]  

  • 13. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibiotics in late clinical development.
    Fernandes P; Martens E
    Biochem Pharmacol; 2017 Jun; 133():152-163. PubMed ID: 27687641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antibiotic pipeline: reviving research and development and speeding drugs to market.
    Luepke KH; Mohr JF
    Expert Rev Anti Infect Ther; 2017 May; 15(5):425-433. PubMed ID: 28306360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery research: the scientific challenge of finding new antibiotics.
    Livermore DM;
    J Antimicrob Chemother; 2011 Sep; 66(9):1941-4. PubMed ID: 21700626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antibacterial research and development in the 21(st) Century--an industry perspective of the challenges.
    Thomson CJ; Power E; Ruebsamen-Waigmann H; Labischinski H
    Curr Opin Microbiol; 2004 Oct; 7(5):445-50. PubMed ID: 15451498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The abandonment of antibacterials: why and wherefore?
    Shlaes DM
    Curr Opin Pharmacol; 2003 Oct; 3(5):470-3. PubMed ID: 14559090
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Academic-industrial partnerships in drug discovery in the age of genomics.
    Harris T; Papadopoulos S; Goldstein DB
    Trends Biotechnol; 2015 Jun; 33(6):320-2. PubMed ID: 25987446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibiotic resistance--action to promote new technologies: report of an EU Intergovernmental Conference held in Birmingham, UK, 12-13 December 2005.
    Finch R; Hunter PA
    J Antimicrob Chemother; 2006 Sep; 58 Suppl 1():i3-i22. PubMed ID: 17003063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.